New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
10:51 EDTEW, MDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Shares of cardiovascular technology company Edwards Lifesciences (EW) are rising today after a U.S. district court granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the U.S. Shares of Medtronic, meanwhile, are falling following the news. WHAT'S NEW: On April 12, Edwards said a U.S. district court in Delaware granted a preliminary injunction, to go into effect in seven days, limiting the sale of Medtronic's CoreValue system in the U.S. In addition, the court ordered Medtronic and Edwards to enter into immediate talks to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant, free from the limitations of the injunction. Medtronic responded on April 13 by saying that the ruling has no impact on the sale or marketing of CoreValue outside of the U.S. or the use of CoreValue in the current U.S. clinical trials. Medtronic is appealing the court's injunction and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. ANALYST REACTION: JPMorgan upgraded Edwards Lifesciences to Neutral from Underweight following the news and raised its price target for shares to $78 from $60. JPMorgan also downgraded Medtronic to Neutral and lowered its price target on that stock to $64 from $69. Another firm, CRT Capital, also upgraded Edwards Lifesciences in response to the news. CRT Capital analyst Shagun Chadha feels that the court decision to grant a preliminary injunction against MDT’s CoreValve focuses the market balance in favor of Edwards and took the stock up to Buy from Fair Value with a price target of $87. Canaccord Genuity analyst Jason Mills said that Edwards achieved a "surprising" and noteworthy win in the courts. Mills noted, however, that he still foresees Edwards to cash in via other forms of equitable relief in lieu of a final injunction. The firm is maintaining its 12-month price target of $84 on Edwards Lifesciences shares. PRICE ACTION: During morning trading, shares of Edwards Lifesciences were up $10.01 or 13.72% to $82.98. Shares of Medtronic fell $1.28 or 2.16% to $57.92.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:37 EDTMDTFlex Pharma announces investment from Medtronic
Subscribe for More Information
March 2, 2015
12:59 EDTMDTAppeals court ruling a positive for NuVasive, says Wells Fargo
Subscribe for More Information
12:54 EDTMDTNuVasive gets mixed appeals court ruling in patent fight with Medtronic
Subscribe for More Information
08:55 EDTMDT, EWEdwards Lifesciences Medtronic likely to get positive catalyst, says Wells Fargo
Subscribe for More Information
February 27, 2015
09:02 EDTMDTMedtronic announces Irish High Court approval of share premium reduction
Subscribe for More Information
February 24, 2015
13:02 EDTMDTMedtronic confirms FDA approval of VenaSeal closure system
Subscribe for More Information
February 23, 2015
08:40 EDTMDTMedtronic acquires Advanced Uro-Solutions, terms not disclosed
Medtronic announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
February 20, 2015
12:19 EDTMDTFDA approves closure system to permanently treat varicose veins
Subscribe for More Information
February 19, 2015
16:15 EDTMDTMedtronic SANTE trial data show sustained safety, improvements in QOLIE-31
Subscribe for More Information
February 17, 2015
09:29 EDTMDTMedtronic says FY16 constant currency revenue may be up mid-single digit range
Subscribe for More Information
09:27 EDTMDTMedtronic, Covidien targeting over $850M in cost synergies through FY18
Subscribe for More Information
08:49 EDTMDTMedtronic sees being at high end of Q4 revenue growth range
Subscribe for More Information
07:19 EDTMDTMedtronic sees Q4 revenue up 4%-6%
Subscribe for More Information
07:18 EDTMDTMedtronic reports Q3 EPS $1.01, consensus 97c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use